A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.

A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results. Br J Haematol. 2017 08; 178(4):561-570.

View in: PubMed

subject areas

Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Carmustine
Child
Cytarabine
Dose-Response Relationship, Drug
Etoposide
Female
Follow-Up Studies
Graft Survival
Hematopoietic Stem Cell Transplantation
Humans
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Male
Melphalan
Middle Aged
Neoplasms, Second Primary
Recurrence
Rituximab
Survival Analysis
Treatment Outcome
Young Adult

authors with profiles

RICHARD E CHAMPLIN
PARTOW KEBRIAEI
PAOLO ANDERLINI
UDAY R POPAT
CHITRA HOSING
ELIZABETH SHPALL
MUZAFFAR H QAZILBASH
AMIN MAJID ALOUSI
YAGO NIETO